NLRP3 and Alzheimer disease: However, it remains unclear whether oral administration of STAE can provide protection against AD‐related neuroinflammation and oxidative stress induced by Aβ25‐35 and whether the SIRT6/NLRP3 signaling pathway is involved in the beneficial effects of STAE on AD.